TMCnet News
Tolero Pharmaceuticals' Alvocidib Selected as 'Top 10 Most Interesting Oncology Project to Watch' for the Therapeutic Area Partnerships ConferenceSALT LAKE CITY --(Business Wire)-- Tolero Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing treatments for oncology and hematologic diseases, today announced that its lead compound alvocidib has been chosen as one of the 'Top 10 Most Interesting Oncology Projects to Watch' for the Therapeutic Area Partnerships conference taking place in Boston, MA November 19-21, 2014. As a result of this designation, David Bearss, Ph.D., founder and CEO of Tolero Pharmaceuticals, will present a corporate overview and information about alvocidib, a multi cyclin-dependent kinase (CDK) small molecule inhibitor, at 1:00 PM on November 20, 2014. Products selected as one of the Most Interesting Oncology Projects to Watch have met rigorous criteria, including unmet medical need, market potential, diversity of indications, strong science, partnering opportunities, and potential for new opportunities beyond initial indications.
About Alvocidib
About Tolero
|